YSOPIA Bioscience

YSOPIA Bioscience is a French clinical stage biotech company specializing in the research and development of therapeutic innovations harnessing the potential of the gut microbiome. 
 
Founded in 2010, YSOPIA develops groundbreaking biotherapies using single-strain keystone bacteria. Yso1 is the company's most advanced development program. After demonstrating strong efficacy results in preclinical animal models, YSOPIA successfully completed the Phase 1 clinical study for its Xla1 biotherapy in July 2021 and demonstrated its excellent safety and tolerability profile, as well as first biological activity.YSOPIA’s portfolio also includes three other innovative programs addressing chronic indications with substantial unmet medical needs (Crohn's disease, mood disorders, cancer).

Supported by leading venture capital investors, such as Seventure Partners, and family offices, YSOPIA Bioscience has established collaborative projects worldwide with renowned scientific institutions and academic experts to maintain the highest standards in the development of its innovative biotherapeutics.